Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
$1.90
-$0.01(-0.44%)
At close: 4:00 PM EST
$1.90
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $2.82
Previous CloseN/A
Volume74.47K
Average Volume (3M)805.94K
Market Cap
$59.67M
Enterprise Value$48.60M
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$229.17K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,948,605
10 Day Avg. Volume1,208,726
30 Day Avg. Volume805,942
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue590.95
Enterprise Value/Gross Profit-764.05
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$6.80Price Target Upside257.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAustralian health authorities have approved an extension to the trial; patients can be treated for up to 12 months.
Financial StabilityGain Therapeutics raised $7M from a stock and warrants offering, providing financial support into early 2026 and past key trial data releases.
Safety ProfileThe independent Data Monitoring Committee has identified no safety concerns and recommended continuing the study with no changes.
Bears Say
Financial PerformanceThe company reported a wider net loss than forecasted, primarily due to higher-than-expected operating expenses.
Operational RisksRisks include potential delays in advancing preclinical candidates, unexpected safety issues, negative trial results, and failure to obtain regulatory approvals.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.41 and its highest was $2.82 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $59.67M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 131 days.
How were Gain Therapeutics’s earnings last quarter?
Currently, no data Available
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 35,948,605 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.80 (257.89% Upside)
$6.80 (257.89% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 81.1%
Last 30 Days ▲ 81.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.49%
12-Months-Change
Fundamentals
Return on Equity
-240.21%
Trailing 12-Months
Asset Growth
-48.77%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$6.80
▲(257.89% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.56%
Insiders
2.22% Mutual Funds
2.23% Other Institutional Investors
90.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---